Tesaro Inc., of Boston, announced that it signed an agreement with Amgen Inc., of Thousand Oaks, Calif., that grants Tesaro exclusive worldwide rights for the development, manufacture, commercialization and distribution of small-molecule inhibitors of anaplastic lymphoma kinase (ALK). Tesaro said it plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small-cell lung cancer whose tumors are ALK-positive.